Search - tctmd.com

Displaying 121 - 140 of 162

Sort: Relevancy | Date

Presentation TCT 2016

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

Presenter: Eugene H. Blackstone, Robert W. Yeh, Kirk N. Garratt

October 30, 2016

Presentation TCT 2016

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Presenter: Mayank Yadav

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation TCT 2016

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Ziad A. Ali

October 30, 2016

Presentation TCT 2015

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Clinician's Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Eric R. Bates

October 12, 2015

Presentation TCT 2015

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Trialist/Guideline Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, John A. Bittl

October 12, 2015

Presentation TCT 2015

A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention

Presenter: Shigeru Saito, Gregg W. Stone, Ron Waksman, Shigeru Saito

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Presenter: Stuart J. Pocock, Jan Tijssen, John L. Petersen

October 11, 2015

Presentation TVT 2015

Insights From the US TVT Registry

Presenter: John D. Carroll

June 05, 2015

Presentation TVT 2015

NOTION in All-Comers

Presenter: Lars Sondergaard

June 05, 2015

Presentation TVT 2015

CoreValve US 2-Year Follow-up

Presenter: Michael J. Reardon

June 05, 2015

Presentation TVT 2015

PARTNER 5-Year Follow-up

Presenter: Martin B. Leon

June 05, 2015

Presentation TVT 2015

Bicuspid Aortic Valve Disease

Presenter: Mathew Williams

June 05, 2015

Presentation TVT 2015

GARY

Presenter: Helge Möllmann

June 05, 2015

Presentation TVT 2015

FRANCE 2

Presenter: Helene Eltchaninoff

June 05, 2015

Presentation TVT 2015

UK Registry

Presenter: Neil E. Moat

June 05, 2015

Advertisement

Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Clinician's Perspective

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Trialist/Guideline Perspective

A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Insights From the US TVT Registry

NOTION in All-Comers

CoreValve US 2-Year Follow-up

PARTNER 5-Year Follow-up

Bicuspid Aortic Valve Disease

GARY

FRANCE 2

UK Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content